AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.